Related Experiment Videos
Saccadic peak velocity and EEG as end-points for a serotonergic challenge test
Harm J Gijsman1, Joop M A van Gerven, Robbert Jan Verkes
1Centre for Human Drug Research, Leiden, The Netherlands. harm.gijsman@doctors.org.uk
Human Psychopharmacology
|October 31, 2002
Summary
The serotonin releaser dexfenfluramine enhanced saccadic peak velocity and decreased electroencephalographic (EEG) activity in male subjects. These findings suggest saccadic eye movements and EEG are valuable indicators of serotonergic drug effects.
Area of Science:
- Neuroscience
- Psychopharmacology
- Neuroimaging
Background:
- Previous research indicated that meta-chlorophenylpiperazine, a serotonin receptor agonist, influences saccadic eye movements and electroencephalographic (EEG) activity.
- Serotonergic pathways are implicated in various cognitive and motor functions.
Purpose of the Study:
- To investigate the effects of dexfenfluramine, a serotonin releaser, on saccadic eye movements and EEG.
- To explore the potential of saccadic peak velocity and EEG as endpoints for assessing serotonergic activity.
Main Methods:
- A double-blind, placebo-controlled, randomized cross-over study was conducted.
- Sixty-two male participants (18-30 years) with varying histories of ecstasy use were administered a single dose of dexfenfluramine.
- Saccadic eye movements and EEG were measured hourly for up to 6 hours.
Main Results:
- Dexfenfluramine administration led to an increase in saccadic peak velocity.
- A decrease in alpha, delta, and theta EEG activity was observed.
- The reduction in EEG activity was more pronounced in heavy users of ecstasy.
Conclusions:
- Saccadic peak velocity and EEG measurements serve as effective endpoints for evaluating serotonergic challenges.
- These findings extend the understanding of serotonergic effects beyond hypothalamic projections.
- The study supports the utility of these neurophysiological measures in psychopharmacological research.